Related Experiment Video

Updated: Jun 27, 2026

Assessing Cellular Target Engagement by SHP2 (PTPN11) Phosphatase Inhibitors
08:45

Assessing Cellular Target Engagement by SHP2 (PTPN11) Phosphatase Inhibitors

Published on: July 17, 2020

Simultaneous blockade of AP-1 and phosphatidylinositol 3-kinase pathway in non-small cell lung cancer cells

J Kikuchi1, I Kinoshita, Y Shimizu

  • 1First Department of Medicine, Hokkaido University School of Medicine, Sapporo, Japan.

British Journal of Cancer
|November 20, 2008
PubMed

Insights

Blocking AP-1 (activator protein-1) with TAM67 enhances PI3K/Akt pathway inhibition, significantly reducing non-small cell lung cancer (NSCLC) growth and cell cycle progression.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Signaling

Background:

  • c-Jun, a key component of the AP-1 transcription factor, is often overexpressed in non-small cell lung cancers (NSCLCs).
  • Previous studies demonstrated that inhibiting AP-1 via a dominant-negative c-Jun mutant (TAM67) suppresses NSCLC cell proliferation.
  • The PI3K/Akt pathway is crucial for NSCLC cell transformation, proliferation, survival, and metastasis.

Purpose of the Study:

  • To investigate the combined effects of AP-1 inhibition and PI3K pathway blockade on NSCLC cell growth.
  • To elucidate the molecular mechanisms underlying the interplay between AP-1 and PI3K/Akt signaling in NSCLC.

Main Methods:

  • Utilized NCI-H1299 Tet-on cells engineered to express TAM67 under an inducible promoter.
  • Administered the PI3K inhibitor LY294002 and assessed its effects on cell growth, Akt phosphorylation, and cell cycle distribution.
  • Evaluated the impact of TAM67 and LY294002 on AP-1 DNA-binding activity, cyclin A levels, p27(Kip1) accumulation, and anchorage-independent growth.

Main Results:

  • LY294002 inhibited H1299 cell growth dose-dependently, with enhanced inhibition observed when combined with TAM67.
  • TAM67 treatment potentiated LY294002-induced Akt dephosphorylation and reduced phosphorylated c-Jun's DNA-binding activity.
  • The combination of TAM67 and LY294002 induced G1 cell cycle arrest, partly due to decreased cyclin A and increased p27(Kip1).
  • Both agents synergistically inhibited anchorage-independent growth of H1299 cells.

Conclusions:

  • The AP-1 and PI3K/Akt signaling pathways are essential for the proliferation of certain NSCLC cells.
  • Combined inhibition of AP-1 and PI3K/Akt pathways represents a promising therapeutic strategy for NSCLC.
  • Targeting both pathways may overcome resistance mechanisms and improve treatment efficacy in NSCLC.

More Related Videos

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays13:22

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Published on: October 23, 2019

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

Related Concept Videos

Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
Phosphoinositides and PIPs01:42

Phosphoinositides and PIPs

Phosphoinositides are a group of phospholipids containing a glycerol backbone with two fatty acid chains and a phosphate attached to a myoinositol sugar ring. The inositol head group extends into the cytoplasm, where it is modified by adding phosphate groups to form phosphatidylinositol phosphates or PIPs.
Different phosphoinositides are synthesized and recruited on the cytosolic face of the plasma membrane. The localization of specific phosphoinositides concentrated in separate membrane...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...